Next Article in Journal / Special Issue
Systems Biology Approach for Cancer Vaccine Development and Evaluation
Previous Article in Journal
Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
Previous Article in Special Issue
Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine
Article Menu

Export Article

Open AccessArticle
Vaccines 2015, 3(3), 519-543; doi:10.3390/vaccines3030519

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)

1
Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
2
Department of Pharmacology, Emory University and Winship Cancer Institute, Atlanta, GA 30322, USA
3
Molecular and Systems Pharmacology Program, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA 30322, USA
4
James Cancer Hospital and Solove Research Institute and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Mary Lenora (Nora) Disis
Received: 4 April 2015 / Revised: 29 June 2015 / Accepted: 29 June 2015 / Published: 6 July 2015
(This article belongs to the Special Issue Cancer Vaccines)
View Full-Text   |   Download PDF [969 KB, uploaded 6 July 2015]   |  

Abstract

Despite the promise of targeted therapies, there remains an urgent need for effective treatment for esophageal cancer (EC) and triple-negative breast cancer (TNBC). Current FDA-approved drugs have significant problems of toxicity, safety, selectivity, efficacy and development of resistance. In this manuscript, we demonstrate that rationally designed peptide vaccines/mimics are a viable therapeutic strategy for blocking aberrant molecular signaling pathways with high affinity, specificity, potency and safety. Specifically, we postulate that novel combination treatments targeting members of the EGFR family and IGF-1R will yield significant anti-tumor effects in in vitro models of EC and TNBC possibly overcoming mechanisms of resistance. We show that the combination of HER-1 and HER-2 or HER-1 and IGF-1R peptide mimics/vaccine antibodies exhibited enhanced antitumor properties with significant inhibition of tumorigenesis in OE19 EC and MDA-MB-231 TNBC cell lines. Our work elucidates the mechanisms of HER-1/IGF-1R and HER-1/HER-2 signaling in these cancer cell lines, and the promising results support the rationale for dual targeting with HER-1 and HER-2 or IGF-1R as an improved treatment regimen for advanced therapy tailored to difference types of cancer. View Full-Text
Keywords: peptide mimics; epitopes; antibodies; immunogenicity; resistance; vaccine candidates; peptide vaccines peptide mimics; epitopes; antibodies; immunogenicity; resistance; vaccine candidates; peptide vaccines
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Overholser, J.; Ambegaokar, K.H.; Eze, S.M.; Sanabria-Figueroa, E.; Nahta, R.; Bekaii-Saab, T.; Kaumaya, P.T. Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines 2015, 3, 519-543.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top